Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UCSD Research May Lead to Targeted Treatment for Asthma Sufferers

30.11.2005


The bronchial tubes of a patient with severe asthma can become scarred due to repeated episodes of allergic inflammation in the airways. The scarring results in blocked airways, excessive production of mucus, and shortness of breath.



Researchers at the University of California, San Diego (UCSD) School of Medicine have discovered that when a single gene – IKK beta – is selectively inactivated in the membrane-lining cells of the bronchial tubes of mice that later inhale allergens, such scarring, mucus production and airway inflammation is significantly reduced.

David H. Broide, M.B.,Ch.B., Professor in UCSD’s Department of Medicine, and Michael Karin, Ph.D., Professor in UCSD’s Department of Pharmacology and the Laboratory of Gene Regulation and Signal Transduction, will publish their findings in the December 6 issue of the Proceedings of the National Academy of Sciences.


“This finding is significant because it suggests that if we can produce a drug that inhibits IKK beta – for example, a drug that is inhaled to target only the patient’s bronchial tubes and not their immune cells – then the scarring, inflammation, and mucus production in asthma could be significantly reduced,” said Broide.

IKK beta is a master regulator gene that is expressed in cells throughout the body including cells lining the bronchial tubes and immune cells, which are needed to fight infection. Through its effects on the transcription factor NF-kB, IKK beta also regulates the expression of many additional genes important to the induction of airway inflammation in asthma.

Using gene-targeting strategies, the UCSD team selectively inactivated the IKK beta gene only in the mouse airway membrane-lining cells, called epithelial cells, but not in other cells outside the airway that also express the gene, such as immune cells. The researchers were able to demonstrate that mice lacking the IKK beta gene in these lining cells had significantly less airway inflammation, mucus production and scarring of bronchial tubes after repeatedly inhaling an allergen.

The researchers set out to explore selective inactivation of IKK beta in the airway because blocking IKK beta throughout the body to prevent the damaging effects of asthma could also suppress the patient’s immune system, resulting in infections.

“An inhaled IKK beta antagonist could theoretically be designed that would not be absorbed into the blood stream, where it would affect the patient’s immune cell function. Such a selective targeting of the drug to the airway would be able to reduce airway inflammation, mucus production, and scarring of the bronchial tubes, with reduced potential for negative side effects.” said Broide.

While only about 10 percent of asthma patients have severe symptoms which lead to scarring of the bronchial tubes, new therapies to prevent scarring are needed, since these patients account for about half of the health costs associated with asthma. As patients with Chronic Obstructive Pulmonary Disease also suffer from mucus production and scarring of their lungs, an inhaled IKK beta antagonist could potentially prove beneficial in such patients.

This research was funded by a National Institutes of Health grant from the National Institute of Allergy and Infectious Diseases, and a grant from the Sandler Program for Asthma Research. Additional contributors to the paper include members of the Broide Laboratory, Jae Youn Cho, M.D., Ph,D,; Marina Miller, M.D., Ph.D.; Taylor Doherty, M.D.; Kirsti McElwain, B.S.; and Shauna McElwain, B.S., and Toby Lawrence, Ph.D. a visiting scientist in the Karin laboratory.

Debra Kain | EurekAlert!
Further information:
http://www.ucsd.edu

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>